Celgene to Acquire Delinia with Goal of Moving Immunotherapy for Lupus into Testing

Celgene Corporation announced that it has entered into an agreement to acquire Delinia, a biotech developing therapeutics for autoimmune diseases, including systemic lupus erythematosus (SLE). The acquisition will expand Celgene’s inflammation and immunology pipeline of potential next-generation medicines, including Delinia’s lead program, DEL106. DEL106 is a potent and highly…